Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in obese, nondiabetic adults is associated with a markedly reduced risk of developing nonexudative age-related macular degeneration (AMD).
The protective effect of GLP-1RAs persists at 5, 7, and 10 years of follow-up compared to other weight-loss drugs (OWLDs).
GLP-1RA treatment does not appear to influence progression from nonexudative to exudative AMD.
Findings highlight potential ocular benefits of GLP-1RAs outside diabetes and support further prospective trials in diverse populations.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
